Cisplatin-based adjuvant chemotherapy remains the standard of care for patients with
resected stage II or III non–small-cell lung cancer. However, biomarker-informed clinical …

Despite the rapidly evolving treatment landscape in advanced non-small-cell lung cancer
(NSCLC), developments in neoadjuvant and adjuvant treatments have been nascent by …

To date, there is no approved biomarker for predicting pathological response in neoadjuvant
programmed cell death (ligand) 1 (PD-(L) 1) blockades treated early-stage non-small cell …

Background The IONESCO (IFCT-1601) trial assessed the feasibility of neoadjuvant
durvalumab, for early-stage resectable non-small-cell lung cancer (NSCLC). Methods In a …

Background In recent years, a series of clinical trials have explored the application of
neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer …

The treatment scenario for patients with resectable non–small cell lung cancer has changed
dramatically with the incorporation of immunotherapy. The introduction of immunotherapy …

Simple Summary The management strategy for the treatment of non-small-cell lung cancer
(NSCLC) has been transformed by our improved understanding of the cancer biology and …

Historically, non-small-cell lung cancer (NSCLC) has been regarded as a nonimmunogenic
tumor; however, recent studies have shown that NSCLCs are among the most responsive …

Lung cancer mortality has decreased over the past decade and can be partly attributed to
advances in targeted therapy and immunotherapy. Immune checkpoint inhibitors (ICIs) have …

In the last decade, immune-checkpoint inhibitors (ICIs) have become the backbone of
therapy in advanced, non-oncogene driven, non-small cell lung cancer (NSCLC). More …